Evoke Pharma Inc (EVOK)
4.50
+0.13
(+3.07%)
USD |
NASDAQ |
Nov 15, 12:31
Evoke Pharma Free Cash Flow (Quarterly): -0.8187M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -0.8187M |
| June 30, 2024 | -0.8206M |
| March 31, 2024 | -2.579M |
| December 31, 2023 | -1.106M |
| September 30, 2023 | -1.042M |
| June 30, 2023 | -1.206M |
| March 31, 2023 | -1.631M |
| December 31, 2022 | -2.506M |
| September 30, 2022 | -1.101M |
| June 30, 2022 | -1.374M |
| March 31, 2022 | -1.615M |
| December 31, 2021 | -1.997M |
| September 30, 2021 | -5.892M |
| June 30, 2021 | -1.510M |
| March 31, 2021 | -2.953M |
| December 31, 2020 | -1.712M |
| September 30, 2020 | -1.810M |
| June 30, 2020 | -1.556M |
| March 31, 2020 | -1.552M |
| December 31, 2019 | -1.148M |
| September 30, 2019 | -1.059M |
| June 30, 2019 | -1.628M |
| March 31, 2019 | -1.927M |
| December 31, 2018 | -1.249M |
| September 30, 2018 | -1.150M |
| Date | Value |
|---|---|
| June 30, 2018 | -1.762M |
| March 31, 2018 | -2.818M |
| December 31, 2017 | -2.734M |
| September 30, 2017 | -2.200M |
| June 30, 2017 | -2.096M |
| March 31, 2017 | -1.687M |
| December 31, 2016 | -1.370M |
| September 30, 2016 | -2.418M |
| June 30, 2016 | -2.230M |
| March 31, 2016 | -2.690M |
| December 31, 2015 | -2.452M |
| September 30, 2015 | -2.504M |
| June 30, 2015 | -2.544M |
| March 31, 2015 | -2.995M |
| December 31, 2014 | -2.521M |
| September 30, 2014 | -3.912M |
| June 30, 2014 | -3.068M |
| March 31, 2014 | -2.001M |
| December 31, 2013 | -1.889M |
| September 30, 2013 | -0.2747M |
| June 30, 2013 | -0.4298M |
| March 31, 2013 | -0.4465M |
| December 31, 2012 | -0.6528M |
| September 30, 2012 | -0.3015M |
| June 30, 2012 | -0.348M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-5.892M
Minimum
Sep 2021
-0.8187M
Maximum
Sep 2024
-1.796M
Average
-1.554M
Median
Free Cash Flow (Quarterly) Benchmarks
| Repligen Corp | 34.79M |
| Eli Lilly and Co | -458.90M |
| MEI Pharma Inc | -18.00M |
| Revance Therapeutics Inc | -41.15M |
| NovaBay Pharmaceuticals Inc | -2.063M |